MedTrace Logo

Tailored Therapy for Hodgkin Lymphoma Using Early Interim Therapy PET for Therapy Decision.

NCT00392314 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 365

Last updated 2014-05-09

No results posted yet for this study

Summary

Recently published studies demonstrated very high event free survival for patients with a normal interim PET/CT and a high hazard ratio for progression of an interim positive (pathological)study. These findings strongly support the integration of interim PET as a decision point for adjustment of chemotherapy.This study use the minimal therapy considered safe according to the predefined risk factors for patients with interim negative PET. Those with pathologic interim study considered as higher risk patients will have dose escalation of therapy.remission rate ,event free survival and overall survival will be evaluated.

Conditions

Interventions

OTHER

PET/CT post 2 cycles of chemotherapy

sintigraphy with PET/CT following 2 cycles of chemotherapy on day 12-14 following chemotherapy

Sponsors & Collaborators

  • Hadassah Medical Organization

    collaborator OTHER

  • Rabin Medical Center

    collaborator OTHER

  • Rambam Health Care Campus

    lead OTHER

Principal Investigators

  • Eldad J Dann, MD · RABMAM medical center ,Haifa Israel , Rappapport school of medicine Technion Israel technical Institute Haifa Israel

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00392314 on ClinicalTrials.gov